To include your compound in the COVID-19 Resource Center, submit it here.

Syros, UCSD team identifies pancreatic cancer targets

Researchers from Syros Pharmaceuticals Inc. (NASDAQ:SYRS) and the University of California San Diego identified targets for pancreatic cancer by using Syros' gene control platform to analyze super-enhancers -- "master switch" transcriptional

Read the full 311 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE